Santarus and Pharming Announce Special Protocol Assessment Agreement with FDA for RHUCIN Phase III Clinical Study

Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV earlier today announced that they have reached agreement with the U.S. Food and Drug Administration on the design of a Phase III clinical study with the investigational drug RHUCIN® (recombinant human C1 inhibitor) under the Special Protocol Assessment process that is intended to support the submission of a Biologics License Application.